Board of Directors

J. Patrick Mackin assumed the position of President and Chief Executive Officer in September 2014, was appointed to the Board of Directors in October 2014, and was appointed Chairman in May 2015. Mr. Mackin has more than 30 years of experience in the medical device industry. Prior to joining Artivion, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe, and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002, Mr. Mackin worked for six years at Genzyme, Inc., serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the US Army. Mr. Mackin received an MBA from Northwestern University’s Kellogg Graduate School of Management and is a graduate of the US Military Academy at West Point.

Thomas F. Ackerman has served as a Director of Artivion since December 2003. Mr. Ackerman currently serves as a financial consultant to Charles River Laboratories International, Inc. Mr. Ackerman served as Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. until August 2015, (NYSE: CRL), a position he held since 2005. Charles River Laboratories is a full-service, early-stage contract research organization. Mr. Ackerman joined Charles River Laboratories in 1988 with over eleven years of combined public accounting and international finance experience. He was named Controller, North America in 1992 and became Vice President and Chief Financial Officer in 1996. In 1999, he was named a Senior Vice President, and in 2005 he was named a Corporate Executive Vice President. Prior to joining Charles River Laboratories, Mr. Ackerman was an accountant at Arthur Andersen & Co. Mr. Ackerman is a Director of the University of Massachusetts Amherst Foundation. Mr. Ackerman received a B.S. in Accounting from the University of Massachusetts and became a certified public accountant in 1979 (his license is currently inactive).

Daniel J. Bevevino has served as a Director of Artivion since December 2003. From 1996 until March of 2008, Mr. Bevevino served as the Vice President and Chief Financial Officer of Respironics, Inc. (Nasdaq: RESP), a company that develops, manufactures, and markets medical devices used primarily for the treatment of patients suffering from sleep and respiratory disorders, where he was employed since 1988. In March 2008, Respironics was acquired by Royal Philips Electronics (NYSE: PHG), whose businesses include a variety of medical solutions including medical diagnostic imaging and patient monitoring systems, as well as businesses focused on energy-efficient lighting and consumer products. From March 2008 to December 31, 2009, Mr. Bevevino was employed by Philips as the Head of Post-Merger Integration – Respironics, as well as in various operating capacities, to help facilitate the integration of the combined companies. He is currently an independent consultant providing interim chief financial officer services and other business advisory services in the life sciences industry, and he currently serves as a director of one of the companies for which he provides services. He began his career as a certified public accountant with Ernst & Young (his license is currently inactive). Mr. Bevevino received a B.S. in Business Administration from Duquesne University and an MBA from the University of Notre Dame.

Marna Borgstrom joined the Artivion Board in June of 2018. She currently serves as the Chief Executive Officer of Yale New Haven Hospital and Yale New Haven Health, positions she has held since 2005. With revenues of $4.5B, Yale New Haven Health is the largest health system in the region, the primary teaching partner of Yale University’s School of Medicine, and the largest private employer in Connecticut.

Marna chairs the boards of the Healthcare Institute and the Coalition to Protect America’s Healthcare and is the immediate past chair of Vizient, a Dallas, Texas-based health care company. She serves on several other boards including The Connecticut Hospital Association and New Haven Promise, an educational initiative designed to increase high school graduation rates and support college tuition for economically disadvantaged students.

Marna received her undergraduate degree from Stanford University and was awarded a master’s of public health by the Yale University School of Epidemiology and Public Health. She is a lecturer at the Yale School of Epidemiology and Public Health, from which she received the Distinguished Alumni Award in 2018.

Jim Bullock has served as a Director of Artivion since October 2016. Jim joined Zyga Technology as President and Chief Executive Officer (CEO) in Nov. 2011. Prior, he served as President and CEO of Atritech, Inc. until it was sold to Boston Scientific and of Endocardial Solutions, Inc., which was acquired by St. Jude Medical. Jim began his career at American Hospital Supply, which was later acquired by Baxter Healthcare. During his 13 years at the company, Jim served in a variety of Sales & Marketing leadership positions. He holds a Bachelor of Science degree in Hospital Administration from the University of Arizona.

Jeff Burbank is the Chief Executive Officer of NxStage Medical Inc., and a member of the Board of Directors. He has served in these positions since he founded the company in December 1998. Jeff has over 30 years of in-depth management experience with companies developing, marketing, and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Jeff co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career, he has been an inventor on over 50 U.S. patents for medical devices. Jeff received his BS in Industrial Engineering from Lehigh University.

Elizabeth A. Hoff joined the Artivion Board of Directors on October 1, 2022. Ms. Hoff has 30 years of experience in the medical device and diagnostics industries and in the commercialization of transformational technologies. Ms. Hoff has served in various senior leadership roles related to, or in, the medical device field, including serving as the Executive Director of Business Development and Strategy at DM Clinical Research and as Chief Executive Officer or as an executive at several medical device start-up companies.

Ms. Hoff also founded Hoff Professional Services where she offered consulting and executive coaching services to medical device leaders. Earlier in her career, she gained in-depth global experience in the aortic space, first at Guidant, leading Guidant’s endovascular expansion in Europe, and then as a Business Unit Leader at W. L. Gore, launching and leading the endovascular AAA and thoracic stent graft programs. She gained further senior executive experience at Medtronic as Vice President and General Manager, where she defined and drove a ten-fold expansion in Medtronic’s implantable cardiac diagnostic platform (now the LinQ product family).

Ms. Hoff received her Bachelor of Arts in Managerial Studies and Psychology from Rice University.

Jon W. Salveson has served as a Director of Artivion since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies (NYSE: PIPR), formerly known as Piper Jaffary Companies. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999, and was named the Group Head of Piper Jaffary international healthcare investment banking group in 2001. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004, and has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson also serves on the Board of CHF Solutions (NASDAQ: CHFS). Mr. Salveson received his undergraduate degree from St. Olaf College and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University.

Mr. Semedo joined the Artivion Board of Directors as of October 1, 2021. He has over 40 years of U.S and international experience in the medical device industry, serving most recently as Senior Vice President & President of Japan Operations at Medtronic, where he led multiple business units and functions. Through his tenure at Medtronic, Mr. Semedo held several executive management positions, including Senior Vice President & President of the company’s Aortic, Peripheral and Venous (APV) Division and Senior Vice President & President of Endovascular Innovations.

He previously served as Vice President of Medtronic’s Japan Cardiovascular Business and as Global Vice President of Vascular Research and Development. Earlier in his career, he spent time at Alaris Medical Systems, Eli Lilly & Co., and Abbott Laboratories. Mr. Semedo received his Bachelor of Science in Engineering from the University of Massachusetts.